Uncategorized

Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher

Published

on

Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to accelerate drug review.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version